List view / Grid view
5 June 2018 | By Dr Zara Kassam (European Pharmaceutical Review), zae
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
30 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...
20 April 2018 | By European Pharmaceutical Review
A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe side effects...
6 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
11 December 2017 | By Steve Bremer (European Pharmaceutical Review)
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
5 December 2017 | By European Pharmaceutical Review
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
9 November 2017 | By European Pharmaceutical Review
A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells.
18 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
6 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
14 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
4 May 2017 | By Niamh Marriott, Junior Editor
The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML...
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer...
Send this to a friend
Follow: